‍

Genetic medicines have transformed from theoretical to transformative. Yet as therapeutic DNA becomes larger, more synthetic and more complex, cells increasingly recognise it as foreign and silence its activity over time.

‍

This natural response limits therapeutic potency, shortens durability and increases dose requirements, creating an invisible biological ceiling that affects the performance and economics of genetic medicines.

‍

At Houdini Bio, we're decoding and engineering around this challenge. Using our AI-powered platform, ARCANA, we redesign therapeutic DNA to avoid cellular silencing while preserving biological function, enabling stronger, longer-lasting expression across genetic medicine programmes.

‍

Our Executive Summary and White Paper explore the biology underpinning therapeutic DNA silencing, the technology we've developed to overcome it, and the opportunity this creates for developers, investors and partners.

‍

What you'll learn

‍

• The biological mechanisms that constrain therapeutic DNA expression in modern genetic medicines.
• How Houdini Bio applies computational DNA engineering to overcome cellular gene silencing.
• Why sustained therapeutic expression could redefine the potency, durability and economics of genetic medicines.

‍

Complete the form below to receive our executive summary and technical white paper.

‍

‍